Market capitalization | $9.48b |
Enterprise Value | $9.52b |
P/E (TTM) P/E ratio | 236.37 |
EV/FCF (TTM) EV/FCF | 59.09 |
EV/Sales (TTM) EV/Sales | 4.25 |
P/S ratio (TTM) P/S ratio | 4.24 |
P/B ratio (TTM) P/B ratio | 2.38 |
Revenue growth (TTM) Revenue growth | 103.89% |
Revenue (TTM) Revenue | $2.24b |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
16 Analysts have issued a Globus Medical, Inc. Class A forecast:
16 Analysts have issued a Globus Medical, Inc. Class A forecast:
Jun '24 |
+/-
%
|
||
Revenue | 2,237 2,237 |
104%
104%
|
|
Gross Profit | 1,233 1,233 |
55%
55%
|
|
EBITDA | 409 409 |
27%
27%
|
EBIT (Operating Income) EBIT | 181 181 |
28%
28%
|
Net Profit | 41 41 |
80%
80%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.
Head office | United States |
CEO | Daniel Scavilla |
Employees | 5,000 |
Founded | 2003 |
Website | www.globusmedical.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.